Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older.~* Patients diagnosed with type 1 or 2 diabetes mellitus.~* Patients diagnosed with DMO with central involvement (defined as the area of the centre subfield of OCT) treated with intravitreal aflibercept (in accordance with routine practice).~* Patients for whom the decision to initiate treatment with intravitreal aflibercept was made as per the investigator's routine treatment practice and prior to study inclusion.~* Patients must provide written informed consent.~Exclusion Criteria:~* Patients under the age of 18.~* Patients with contraindications as listed in the SmPC for intravitreal aflibercept.~* Patients with pre-planned cataract surgery during the observational period.~* Patients previously treated with intravitreal anti-VEGF within 28 days.~* Patients currently or previously treated with systemic anti-VEGF.~* Patients previously treated with intravitreal fluocinolone acetonide steroid.~* Patients participating in an investigational programme with interventions outside of routine clinical practice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 / Anti-VEGF treatment naïve patients (Type: None): Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
- Cohort 2 / Anti-VEGF treatment non-naïve patients (Type: None): Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
- Cohort 3 / Total study population (Type: None): Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.

Based on this trial design, predict the completion outcome and termination type (if applicable).